From Imitation to Innovation: A Study of China’s Drug R&D and Relevant National Policies
July 1, 2011 Editor 0
Research & Development (R&D) plays an increasingly important role in China’s pharmaceutical industry. To gain a competitive edge in the global pharmaceutical market, the current national strategy of China forcefully pushes for independent drug innovations. This article investigates the historical, legal, and institutional contexts in which China’s drug R&D has evolved. Based on an analysis of the drug R&D evolution and national policies in China, it predicts the future trend of China’s policies relevant to drug innovations. This paper helps to understand the impact of national policies on drug R&D in China, which can be used to inform decision-making on investments in China’s pharmaceutical market or conducting technology trade and international cooperation with Chinese partners.
- Future trends in nanotechnology and molecular assembly: conceptualising technological innovation and social impact towards 2025
- Exploring an alternative model for funding Africa’s startup enterprises: Search Funds
- Neglected diseases: Nodding acquaintance
- Use Social Media to Partner with Customers and Improve Service
- Tight contest for .africa domain
- Crowd-funded micro-grants for genomics and an actionable idea connecting small (artisan) science, infrastructure science, and citizen philanthropy.
Subscribe to our stories
- Entrepreneurial Alertness, Innovation Modes, And Business Models in Small- And Medium-Sized Enterprises December 30, 2021
- The Strategic Role of Design in Driving Digital Innovation June 10, 2021
- Correction to: Hybrid mosquitoes? Evidence from rural Tanzania on how local communities conceptualize and respond to modified mosquitoes as a tool for malaria control June 10, 2021
- BRIEF FOCUS: Optimal spacing for groundnuts in smallholder farming systems June 9, 2021
- COVID-19 pandemic: impacts on the achievements of Sustainable Development Goals in Africa June 9, 2021